Investor Presentaiton

50 50 100 150 200 FY94 FY95 FY96 FY97 ROCE 300 250 FY98 Successful track record of turning around acquisitions SUN PHARMA 27% 26% 23% 35% 41% 19% 22% 30% 20% 27% 18% 8 Early Acquisitions 4 Acquisitions Recent Acquisitions Net Sales (Rs Bn) © Sun Pharmaceutical Industries Limited. All Rights Reserved. EBITDA (Rs Bn) FY99 FYOO FY01 FY02 FY03 FY04 FY05 FY06 Chattem Assets of: Taro Dusa Bryan URL Hungary Ranbaxy Able Labs *FY15 numbers include the impact of Ranbaxy merger 15 FY15*

View entire presentation